{"id":12482,"date":"2021-06-22T18:13:55","date_gmt":"2021-06-22T12:43:55","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=12482"},"modified":"2021-07-24T12:58:27","modified_gmt":"2021-07-24T07:28:27","slug":"pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills","title":{"rendered":"Horizon\/ Arrowhead Deal; Dr Reddy&#8217;s Lab\u2019s Drug US Launch; Targovax\u2019s ONCOS-102;  RedHill&#8217;s Oral Opaganib in COVID-19"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f182657234c\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f182657234c\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills\/#Horizon_Dishes_Out_Million_Dollars_to_get_Arrowheads_RNAi_Drug\" >Horizon Dishes Out Million Dollars to get Arrowhead&#8217;s RNAi Drug<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills\/#Dr_Reddys_Labs_Icosapent_Ethyl_Capsules_See_Daylight_in_the_US\" >Dr Reddy&#8217;s Lab\u2019s Icosapent Ethyl Capsules See Daylight in the US<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills\/#Targovaxs_ONCOS-102_Receives_Fast_Track_Designation_in_Melanoma\" >Targovax\u2019s ONCOS-102 Receives Fast Track Designation in Melanoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills\/#RedHill_Biopharma_Assertive_of_its_Oral_Opaganib_in_COVID-19\" >RedHill Biopharma Assertive of its Oral Opaganib in COVID-19<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-horizon-dishes-out-million-dollars-to-get-arrowhead-s-rnai-drug\"><span class=\"ez-toc-section\" id=\"Horizon_Dishes_Out_Million_Dollars_to_get_Arrowheads_RNAi_Drug\"><\/span><strong>Horizon Dishes Out Million Dollars to get Arrowhead&#8217;s RNAi Drug<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Arrowhead Pharmaceuticals and Horizon Therapeutics have announced a research and development collaboration to advance the treatment landscape for uncontrolled gout.<\/p>\n\n\n\n<p>Under the terms and conditions, Arrowhead is bound to receive an upfront sum of USD40 million while lending the exclusive global rights of its short interfering RNA (siRNA) treatment to Horizon. The treatment aims to target xanthine dehydrogenase (XDH) for the treatment of uncontrolled <a href=\"https:\/\/www.delveinsight.com\/report-store\/gout-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">gout<\/a>. Besides, Arrowhead will also be eligible to receive monetization gains on development, regulatory and commercial milestones of upto $660 million, as well as royalties on net product sales in the low- to mid-teens range.<\/p>\n\n\n\n<p>Moreover, Arrowhead will be solely responsible for the activities involved during pre-clinical phases of development, while Horizon will be advancing the asset further towards clinical phases of trials along with the commercialization of the drug.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-dr-reddy-s-lab-s-icosapent-ethyl-capsules-see-daylight-in-the-us\"><span class=\"ez-toc-section\" id=\"Dr_Reddys_Labs_Icosapent_Ethyl_Capsules_See_Daylight_in_the_US\"><\/span><strong>Dr Reddy&#8217;s Lab\u2019s Icosapent Ethyl Capsules See Daylight in the US<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Dr. Reddy\u2019s Laboratories announced the launch of Icosapent Ethyl Capsules of strength 1 gram to reduce triglyceride (TG) levels in severe (\u2265 500 mg\/dL) hypertriglyceridemia in adult patients.&nbsp;<\/p>\n\n\n\n<p>The drug is not approved as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (\u2265 150 mg\/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for <a href=\"https:\/\/www.delveinsight.com\/blog\/burden-of-global-cardiovascular-diseases\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">cardiovascular disease.<\/a><\/p>\n\n\n\n<p>Listed limitations of the drug include risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-targovax-s-oncos-102-receives-fast-track-designation-in-melanoma\"><span class=\"ez-toc-section\" id=\"Targovaxs_ONCOS-102_Receives_Fast_Track_Designation_in_Melanoma\"><\/span><strong>Targovax\u2019s ONCOS-102 Receives Fast Track Designation in Melanoma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The USFDA grants Fast Track Designation to Targovax\u2019s&nbsp; ONCOS-102 under investigations for PD-1-refractory advanced melanoma from the US FDA. Targovax is a clinical-stage immune-oncology company that is developing immune activators to target hard-to-treat solid tumors.&nbsp;<\/p>\n\n\n\n<p>The designation was granted on the basis of the promising evidence demonstrated by the drug in inducing immune activation and generating tumor responses. The drug has already been awarded the same designation, however, in <a href=\"https:\/\/www.delveinsight.com\/report-store\/malignant-pleural-mesothelioma-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">malignant pleural mesothelioma<\/a>.<\/p>\n\n\n\n<p>The additional destination coupled with the existing one further amplifies the PD-1-refractory <a href=\"https:\/\/www.delveinsight.com\/report-store\/advanced-melanoma-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">advanced melanoma<\/a>.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-redhill-biopharma-assertive-of-its-oral-opaganib-in-covid-19\"><span class=\"ez-toc-section\" id=\"RedHill_Biopharma_Assertive_of_its_Oral_Opaganib_in_COVID-19\"><\/span><strong>RedHill Biopharma Assertive of its Oral Opaganib in COVID-19<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>RedHill Biopharma announced the presentation of the positive Phase 2 safety and efficacy data of its oral drug, <strong>Opaganib, <\/strong>in hospitalized patients with <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus-vaccine-candidates\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19<\/a> pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).<\/p>\n\n\n\n<p>As per the presentation of the data from a&nbsp; 40-patient U.S. Phase 2 study titled <em>&#8220;Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlled Phase 2A Study, in Adult Subjects Hospitalized with SARS-CoV-2 Positive Pneumonia (NCT: 04414618)&#8221;, <\/em>the drug managed to shine and ought to emerge as the first novel, oral therapy in the treatment of COVID-19 in a large late-stage study. The drugmaker shows full confidence in its drug and plans to advance to a phase II\/III study for which the enrollment has already been done.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Horizon Dishes Out Million Dollars to get Arrowhead&#8217;s RNAi Drug Arrowhead Pharmaceuticals and Horizon Therapeutics have announced a research and development collaboration to advance the treatment landscape for uncontrolled gout. Under the terms and conditions, Arrowhead is bound to receive an upfront sum of USD40 million while lending the exclusive global rights of its short [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":12491,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1962,143,12514,704,17073,17072,17074,2271,17075],"industry":[17225],"therapeutic_areas":[17235,17230,17245,17228],"class_list":["post-12482","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-arrowhead-pharmaceuticals","tag-cardiovascular-disease","tag-covid-19-treatment","tag-fda","tag-gout-market","tag-horizon-therapeutics","tag-melanoma-market","tag-redhill-biopharma","tag-targovax","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Horizon\/ Arrowhead Deal; RedHill&#039;s Oral Opaganib in COVID-19<\/title>\n<meta name=\"description\" content=\"Horizon\/ Arrowhead Deal; Dr Reddy&#039;s Lab\u2019s Drug US Launch; Targovax\u2019s ONCOS-102; RedHill&#039;s Oral Opaganib in COVID-19\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Horizon\/ Arrowhead Deal; RedHill&#039;s Oral Opaganib in COVID-19\" \/>\n<meta property=\"og:description\" content=\"Horizon\/ Arrowhead Deal; Dr Reddy&#039;s Lab\u2019s Drug US Launch; Targovax\u2019s ONCOS-102; RedHill&#039;s Oral Opaganib in COVID-19\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-22T12:43:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/22185018\/Horizon-Arrowhead-deal-Dr-Reddy-Lab-Drug-US-Launch-Targovax-ONCOS-102-RedHill-Oral-Opaganib-COVID-19-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Horizon\/ Arrowhead Deal; RedHill's Oral Opaganib in COVID-19","description":"Horizon\/ Arrowhead Deal; Dr Reddy's Lab\u2019s Drug US Launch; Targovax\u2019s ONCOS-102; RedHill's Oral Opaganib in COVID-19","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills","og_locale":"en_US","og_type":"article","og_title":"Horizon\/ Arrowhead Deal; RedHill's Oral Opaganib in COVID-19","og_description":"Horizon\/ Arrowhead Deal; Dr Reddy's Lab\u2019s Drug US Launch; Targovax\u2019s ONCOS-102; RedHill's Oral Opaganib in COVID-19","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-06-22T12:43:55+00:00","article_modified_time":"2021-07-24T07:28:27+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/22185018\/Horizon-Arrowhead-deal-Dr-Reddy-Lab-Drug-US-Launch-Targovax-ONCOS-102-RedHill-Oral-Opaganib-COVID-19-1.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills","name":"Horizon\/ Arrowhead Deal; RedHill's Oral Opaganib in COVID-19","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/22185018\/Horizon-Arrowhead-deal-Dr-Reddy-Lab-Drug-US-Launch-Targovax-ONCOS-102-RedHill-Oral-Opaganib-COVID-19-1.png","datePublished":"2021-06-22T12:43:55+00:00","dateModified":"2021-07-24T07:28:27+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Horizon\/ Arrowhead Deal; Dr Reddy's Lab\u2019s Drug US Launch; Targovax\u2019s ONCOS-102; RedHill's Oral Opaganib in COVID-19","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-horizon-arrowhead-reddys-targovaxs-redhills#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/22185018\/Horizon-Arrowhead-deal-Dr-Reddy-Lab-Drug-US-Launch-Targovax-ONCOS-102-RedHill-Oral-Opaganib-COVID-19-1.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/22185018\/Horizon-Arrowhead-deal-Dr-Reddy-Lab-Drug-US-Launch-Targovax-ONCOS-102-RedHill-Oral-Opaganib-COVID-19-1.png","width":772,"height":482,"caption":"Horizon-Arrowhead-deal-Dr-Reddy-Lab-Drug-US-Launch-Targovax-ONCOS-102;-RedHill-Oral-Opaganib-COVID-19"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/22185018\/Horizon-Arrowhead-deal-Dr-Reddy-Lab-Drug-US-Launch-Targovax-ONCOS-102-RedHill-Oral-Opaganib-COVID-19-1-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Arrowhead Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cardiovascular disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19 Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gout Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Horizon Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Melanoma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">RedHill Biopharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Targovax<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Arrowhead Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Cardiovascular disease<\/span>","<span class=\"advgb-post-tax-term\">COVID-19 Treatment<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Gout Market<\/span>","<span class=\"advgb-post-tax-term\">Horizon Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Melanoma Market<\/span>","<span class=\"advgb-post-tax-term\">RedHill Biopharma<\/span>","<span class=\"advgb-post-tax-term\">Targovax<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 22, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 22, 2021 6:13 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"Horizon-Arrowhead-deal-Dr-Reddy-Lab-Drug-US-Launch-Targovax-ONCOS-102;-RedHill-Oral-Opaganib-COVID-19","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=12482"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12482\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/12491"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=12482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=12482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=12482"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=12482"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=12482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}